Reuters logo
BRIEF-‍Morphotek announces agreement with Fujirebio Diagnostics to commercialize CA125 II assay as companion diagnostic for Farletuzumab​
2017年9月5日 / 下午2点44分 / 17 天前

BRIEF-‍Morphotek announces agreement with Fujirebio Diagnostics to commercialize CA125 II assay as companion diagnostic for Farletuzumab​

Sept 5 (Reuters) - Morphotek:

* Announces agreement with Fujirebio Diagnostics, Inc. to commercialize CA125 II assay as a companion diagnostic for Farletuzumab​

* Agreement provides Fujirebio with worldwide license to develop, manufacture and commercialize CA125 II assay as a companion diagnostic​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below